These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37059438)

  • 1. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group.
    Sampaio LPB; Manreza MLG; Pessoa A; Gurgel-Giannetti J; Coan AC; Júnior HVL; Embiruçu EK; Henriques-Souza AMM; Kok F
    Arq Neuropsiquiatr; 2023 Mar; 81(3):284-295. PubMed ID: 37059438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
    Nickel M; Gissen P; Greenaway R; Cappelletti S; Hamborg C; Ragni B; Ribitzki T; Schulz A; Tondo I; Specchio N
    Neuropediatrics; 2023 Dec; 54(6):402-406. PubMed ID: 37329878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
    Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
    Gissen P; Specchio N; Olaye A; Jain M; Butt T; Ghosh W; Ruban-Fell B; Griffiths A; Camp C; Sisic Z; Schwering C; Wibbeler E; Trivisano M; Lee L; Nickel M; Mortensen A; Schulz A
    Orphanet J Rare Dis; 2021 May; 16(1):217. PubMed ID: 33980287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world.
    Lourenço CM; Pessoa A; Mendes CC; Rivera-Nieto C; Vergara D; Troncoso M; Gardner E; Mallorens F; Tavera L; Lizcano LA; Atanacio N; Guelbert N; Specola N; Mancilla N; de Souza CFM; Mole SE
    J Paediatr Child Health; 2021 Apr; 57(4):519-525. PubMed ID: 33377563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
    Schulz A; Specchio N; de Los Reyes E; Gissen P; Nickel M; Trivisano M; Aylward SC; Chakrapani A; Schwering C; Wibbeler E; Westermann LM; Ballon DJ; Dyke JP; Cherukuri A; Bondade S; Slasor P; Cohen Pfeffer J
    Lancet Neurol; 2024 Jan; 23(1):60-70. PubMed ID: 38101904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies.
    Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S
    Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management Strategies for CLN2 Disease.
    Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A
    Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment.
    Mortensen A; Raebel EM; Wiseman S
    Orphanet J Rare Dis; 2022 Jan; 17(1):19. PubMed ID: 35045884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.
    Mole SE; Schulz A; Badoe E; Berkovic SF; de Los Reyes EC; Dulz S; Gissen P; Guelbert N; Lourenco CM; Mason HL; Mink JW; Murphy N; Nickel M; Olaya JE; Scarpa M; Scheffer IE; Simonati A; Specchio N; Von Löbbecke I; Wang RY; Williams RE
    Orphanet J Rare Dis; 2021 Apr; 16(1):185. PubMed ID: 33882967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
    Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A
    J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.
    Hammon K; de Hart G; Vuillemenot BR; Kennedy D; Musson D; O'Neill CA; Katz ML; Henshaw JW
    Clin Transl Sci; 2021 Sep; 14(5):1810-1821. PubMed ID: 34076336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
    Gutić M; Milosavljević MN; Safiye T; Milidrag A; Jankovic SM
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):561-570. PubMed ID: 36994735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
    de Los Reyes E; Lehwald L; Augustine EF; Berry-Kravis E; Butler K; Cormier N; Demarest S; Lu S; Madden J; Olaya J; See S; Vierhile A; Wheless JW; Yang A; Cohen-Pfeffer J; Chu D; Leal-Pardinas F; Wang RY
    Pediatr Neurol; 2020 Sep; 110():64-70. PubMed ID: 32684372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.
    Nickel M; Simonati A; Jacoby D; Lezius S; Kilian D; Van de Graaf B; Pagovich OE; Kosofsky B; Yohay K; Downs M; Slasor P; Ajayi T; Crystal RG; Kohlschütter A; Sondhi D; Schulz A
    Lancet Child Adolesc Health; 2018 Aug; 2(8):582-590. PubMed ID: 30119717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.